Aesica to expand formulation development capability
Plans for UK and Germany will almost double capacity
Aesica, a UK provider of development and manufacturing services for formulated products and active pharmaceutical ingredients, has opened a new analytical chemistry laboratory and GMP suite to extend and improve its formulation development capability.
The facilities at Aesica’s site in Nottingham include a laboratory to test inhalation devices, which is vital as inhalation dosage forms currently represent nearly 40% of the firm’s formulation development business.
In addition, the new GMP manufacturing suite will almost double the production capacity of clinical trial materials across all dosage forms.
Aesica also plans to launch a second site from within its formulated products plant in Zwickau, Germany, which specialises in the production of tablets, capsules and pellet/beads and has a well-equipped development laboratory.
The new site is expected to be operational by January 2012.
Paul Titley, managing director, Formulation Development, at Aesica, said: ‘The opening of our new facilities represents a key milestone for the Formulation Development team in Nottingham as it is exactly five years to the day since I launched R5 Pharmaceuticals at CPhI in Paris. Since then we were acquired by Aesica in June 2010 and with the support of the executive team have now come full circle and grown into a new, bigger space to meet growing market demand.’
He added that the new laboratory and expansion of the firm’s service in Germany is ‘strategically crucial for the continued growth and evolution of Aesica’s Formulation Development offering’.
‘Creating a site within the existing plant in Zwickau will also have a significant impact upon business development as it is imperative that we can provide a local service to our German based clients and this expansion into Europe will provide the ideal platform for further growth into the US and Asia next year,’ he said.
